GlassScriptPhysician profile
Ashish Udhrain
NPI 1013980853
$75,527.99
in general payments reported to CMS, 2019-2025
41 companies · $4,524 in 2025
The $4,524 reported for 2025 was more than what 81% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36K · 2020: $14K · 2021: $14K · 2022: $6,178 · 2023: $658 · 2024: $1,043 · 2025: $4,524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,963 · Food and Beverage: $2,130 · Education: $89.99 · Travel and Lodging: $43.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,962.50 |
| Food and Beverage | $2,130.25 |
| Education | $89.99 |
| Travel and Lodging | $43.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $29,518.87 | 2019-2025 | Tagrisso |
| Takeda Pharmaceuticals U.S.A., INC. | $22,618.70 | 2019-2025 | Ninlaro |
| Pfizer INC. | $8,797.31 | 2019-2024 | |
| Genzyme Corporation | $6,428.20 | 2019-2025 | |
| Taiho Oncology, INC. | $1,666.63 | 2020-2021 | |
| Karyopharm Therapeutics INC. | $1,550.00 | 2021 | |
| Astrazeneca Uk Limited | $1,387.50 | 2020 | |
| Daiichi Sankyo INC. | $1,185.12 | 2022-2025 | Enhertu, Datroway |
| Novartis Pharmaceuticals Corporation | $313.05 | 2022-2025 | |
| Beigene USA, INC. | $207.57 | 2022-2024 | Brukinsa |
| Merck Sharp & Dohme LLC | $178.59 | 2019-2025 | Keytruda, Reblozyl |
| Lilly USA, LLC | $148.73 | 2021-2025 | Jaypirca, Verzenio |
| Celgene Corporation | $141.90 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
| Bayer Healthcare Pharmaceuticals INC. | $130.45 | 2022-2025 | |
| Exelixis INC. | $117.83 | 2024-2025 | Cabometyx |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aveo Pharmaceuticals, INC. | $111.16 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.74 | 2019 | |
| Janssen Biotech, INC. | $87.63 | 2022-2025 | Darzalex, Talvey, Tecvayli |
| Astellas Pharma US INC | $81.84 | 2023-2024 | Xtandi |
| Jazz Pharmaceuticals INC. | $80.12 | 2023-2025 | |
| Eisai INC. | $57.03 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $55.57 | 2022-2025 | Camzyos |
| Sobi, INC | $54.35 | 2024-2025 | |
| Abbvie INC. | $52.51 | 2025 | |
| Springworks Therapeutics, INC. | $50.95 | 2024-2025 | Ogsiveo |
| Incyte Corporation | $41.29 | 2024-2025 | Monjuvi, Jakafi |
| Genentech USA, INC. | $39.67 | 2023-2024 | Lunsumio, Columvi, Polivy |
| Seagen INC. | $36.87 | 2019-2020 | |
| Gilead Sciences, INC. | $34.47 | 2021-2022 | |
| Immunocore Limited | $33.56 | 2025 | Kimmtrak |
| Glaxosmithkline, LLC. | $31.30 | 2024-2025 | Ojjaara, Blenrep |
| Stemline Therapeutics INC. | $28.83 | 2023 | Orserdu |
| Ipsen Biopharmaceuticals, INC | $27.40 | 2024 | Somatuline Depot, Onivyde |
| Amgen INC. | $19.67 | 2023 | Lumakras |
| Adc Therapeutics America, INC. | $19.49 | 2023 | |
| Inari Medical, INC. | $19.39 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Dendreon Pharmaceuticals LLC | $18.36 | 2025 | Provenge |
| Puma Biotechnology, INC. | $18.13 | 2025 | |
| Cti Biopharma Corp. | $16.58 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $13.96 | 2025 | Sancuso |
| Myriad Genetic Laboratories, INC. | $13.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashish Udhrain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.